Invitrocue’s Onco-PDO test Receives Approval in Singapore as a Personalized Oncology Service

Image used for information purpose only. Picture Credit:

Invitrocue, a Singapore-based biotechnology and medical innovation company, has achieved a significant advancement in clinical drug testing with its personalized oncology drug test, Onco-PDO. Operating from Invitrocue’s clinical laboratory, which is licensed by the Ministry of Health (MoH), Onco-PDO stands as Singapore’s premier clinical cancer drug screening test. This pioneering test aims to personalize treatments by enhancing the efficiency of chemotherapy regimens through the utilization of patients’ own cancer cells. By doing so, it reduces overall treatment costs and time.

Backed by over eight years of cumulative validation data, the Onco-PDO test is founded upon Invitrocue’s proprietary 3D liver cancer organoid tissue engineering technology. This technology was initially developed through a collaboration with A*STAR’s Institute of Bioengineering and Nanotechnology, Massachusetts Institute of Technology (MIT), and the Genome Institute of Singapore in 2012.

The Onco-PDO test has received CE marking in Europe and, as of February this year, has been granted approval for coverage under National Public Healthcare Insurance in Germany.

The test provides clinicians and oncologists with essential data to prioritize drugs that exhibit optimal efficacy in targeting individual patients’ cancer cells, boasting a positive predictive accuracy of 75 – 80% and a negative prediction rate of over 90%, varying according to cancer type. For patients facing relapses or displaying resistance to multiple treatments, Onco-PDO identifies drugs to which their tumors are either responsive or resistant, thereby enhancing their response to specific cancer therapies.

Presently, the test is available for patients diagnosed with breast, ovarian, lung, colorectal, pancreatic, liver, gastric, and head and neck cancers. Invitrocue is actively exploring opportunities to extend its application to additional cancer types in the near future.

Invitrocue currently operates in Singapore, Hong Kong, and Germany, with a recent expansion into Malaysia. The company intends to further expand its presence into additional countries within the Southeast Asia region and has already received considerable interest from patients and clinicians in the United States.

Read More: Click Here